PJPaula M. Jacobs

Paula M. Jacobs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paula M. Jacobs has a total of 487 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of quantitative imaging analysis methods to evaluate murine [18F]FLT PET therapy response studies

    by J. D. Kalen, J. L. Tatum, P. M. Jacobs, J. H. Doroshow

    Background: Positron Emission Tomography (PET) imaging using 3’-deoxy-3’-[F-18] fluorothymidine (FLT) is a valuable non-invasive marker of tumor proliferation. However, variability in imaging protocols and quantitative analysis techniques hampers comparability across preclinical chemotherapy response studies. Methods: To address this issue in preclinical studies, we evaluated two key areas: (1) imaging standardization (2) semi-quantitative analyses, including Standard Uptake Value (SUV) SUV(max) and SUV(mean), and percent injected (%ID)/g. Using standardized methods of animal handling, image acquisition, image reconstruction and analyses, we assessed multiple FLT uptake metrics in three responsive Patient-Derived Xenograft (PDX) models treated with temozolomide/berzosertib or cisplatin/berzosertib. Metrics included: %ID, SUVbw(max), SUVbw(mean) with a Region of Interest (ROI) threshold of 50% of the maximum value [SUVbw(mean-50%)], and the ratios tumor-to-tissue and tumor-to-liver. Statistical comparisons were made using Brown-Forsythe and Kruskal-Wallis ANOVA and unpaired two tailed t-test to assess cohort differences. Results: Across models and timepoints, no statistical difference among analysis techniques were observed except for one outlier at day 3 in one vehicle cohort, likely due to variability in the normalization parameter. SUVbw(max) and SUVbw(mean-50%) showed the strongest ability to differentiate between vehicle and treated cohorts. Conclusion: Semi-quantitative FLT PET metrics can be harmonized across preclinical studies, with caveats in understanding the normalization parameters, with SUV-based metrics preferred and that larger numbers of animals per cohort will be required to power (≥0.8) robust conclusions. These findings support FLT PET standardization in translational imaging.

  • Open Access

    3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor

    by James L. Tatum, Joseph D. Kalen, Paula M. Jacobs, Lisa A. Riffle, Amy James, Lai Thang, Chelsea Sanders, Melinda G. Hollingshead, Falguni Basuli, Jianfeng Shi, et al.

    Background: Several new generation CDK4/6 inhibitors have been developed and approved for breast cancer therapy in combination with endocrine therapeutics. Application of these inhibitors either alone or in combination in other solid tumors has been proposed, but no imaging biomarkers of response have been reported in non-breast cancer animal models. The purpose of this study was to evaluate 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography (PET) as in vivo biomarker of response to palbociclib in a non-breast cancer model. Methods: Twenty-four NSG mice bearing patient derived xenografts (PDX) of a well-characterized bladder tumor were randomized into 4 treatment groups: vehicle (n = 6); palbociclib (n = 6); temozolomide (n = 6); and palbociclib plus temozolomide (n = 6) and treated with two cycles of therapy or vehicle. Tumor uptake of [18F]FLT was determined by micro-PET/CT at baseline, 3 days, and 9 days post initiation of therapy. Following the second cycle of therapy, the mice were maintained until their tumors reached a size requiring humane termination. Results: [18F]FLT uptake decreased significantly in the palbociclib and combination arms (p = 0.0423 and 0.0106 respectively at day 3 and 0.0012 and 0.0031 at day 9) with stable tumor volume. In the temozolomide arm [18F]FLT uptake increased with day 9 uptake significantly different than baseline (p = 0.0418) and progressive tumor growth was observed during the treatment phase. All groups exhibited progressive disease after day 22, 10 days following cessation of therapy. Conclusion: Significant decreases in [18F]FLT uptake as early as three days post initiation of therapy with palbociclib, alone or in combination with temozolomide, in this bladder cancer model correlates with an absence of tumor growth during therapy that persists until day 18 for the palbociclib group and day 22 for the combination group (6 days and 10 days) following cessation of therapy. These results support early modulation of [18F]FLT as an in vivo biomarker predictive of palbociclib therapy response in a non-breast cancer model.


  • Open Access

    Design and Implementation of the Pre-Clinical DICOM Standard in Multi-Cohort Murine Studies

    by Joseph D. Kalen, David A. Clunie, Yanling Liu, James L. Tatum, Paula M. Jacobs, Justin Kirby, John B. Freymann, Ulrike Wagner, Kirk E. Smith, Christian Suloway, et al.

    The small animal imaging Digital Imaging and Communications in Medicine (DICOM) acquisition context structured report (SR) was developed to incorporate pre-clinical data in an established DICOM format for rapid queries and comparison of clinical and non-clinical datasets. Established terminologies (i.e., anesthesia, mouse model nomenclature, veterinary definitions, NCI Metathesaurus) were utilized to assist in defining terms implemented in pre-clinical imaging and new codes were added to integrate the specific small animal procedures and handling processes, such as housing, biosafety level, and pre-imaging rodent preparation. In addition to the standard DICOM fields, the small animal SR includes fields specific to small animal imaging such as tumor graft (i.e., melanoma), tissue of origin, mouse strain, and exogenous material, including the date and site of injection. Additionally, the mapping and harmonization developed by the Mouse-Human Anatomy Project were implemented to assist co-clinical research by providing cross-reference human-to-mouse anatomies. Furthermore, since small animal imaging performs multi-mouse imaging for high throughput, and queries for co-clinical research requires a one-to-one relation, an imaging splitting routine was developed, new Unique Identifiers (UID’s) were created, and the original patient name and ID were saved for reference to the original dataset. We report the implementation of the small animal SR using MRI datasets (as an example) of patient-derived xenograft mouse models and uploaded to The Cancer Imaging Archive (TCIA) for public dissemination, and also implemented this on PET/CT datasets. The small animal SR enhancement provides researchers the ability to query any DICOM modality pre-clinical and clinical datasets using standard vocabularies and enhances co-clinical studies.


  • Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment

    by David A. Wheeler, Naoko Takebe, Toshinori Hinoue, Katherine A. Hoadley, Maria F. Cardenas, Alina M. Hamilton, Peter W. Laird, Linghua Wang, Adrienne Johnson, Ninad Dewal, et al.


  • Open Access

    The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study

    by Barbara A Conley, Lou Staudt, Naoko Takebe, David A Wheeler, Linghua Wang, Maria F Cardenas, Viktoriya Korchina, Jean Claude Zenklusen, Lisa M McShane, James V Tricoli, et al.

    Background: Tumor molecular profiling from patients experiencing exceptional responses to systemic therapy may provide insights into cancer biology and improve treatment tailoring. This pilot study evaluates the feasibility of identifying exceptional responders retrospectively, obtaining pre-exceptional response treatment tumor tissues, and analyzing them with state-of-the-art molecular analysis tools to identify potential molecular explanations for responses. Methods: Exceptional response was defined as partial (PR) or complete (CR) response to a systemic treatment with population PR or CR rate less than 10% or an unusually long response (eg, duration >3 times published median). Cases proposed by patients’ clinicians were reviewed by clinical and translational experts. Tumor and normal tissue (if possible) were profiled with whole exome sequencing and, if possible, targeted deep sequencing, RNA sequencing, methylation arrays, and immunohistochemistry. Potential germline mutations were tracked for relevance to disease. Results: Cases reflected a variety of tumors and standard and investigational treatments. Of 520 cases, 476 (91.5%) were accepted for further review, and 222 of 476 (46.6%) proposed cases met requirements as exceptional responders. Clinical data were obtained from 168 of 222 cases (75.7%). Tumor was provided from 130 of 168 cases (77.4%). Of 117 of the 130 (90.0%) cases with sufficient nucleic acids, 109 (93.2%) were successfully analyzed; 6 patients had potentially actionable germline mutations. Conclusion: Exceptional responses occur with standard and investigational treatment. Retrospective identification of exceptional responders, accessioning, and sequencing of pretreatment archived tissue is feasible. Data from molecular analyses of tumors, particularly when combining results from patients who received similar treatments, may elucidate molecular bases for exceptional responses.


  • Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study

    by Baris Turkbey, Marcin Czarniecki, Joanna H. Shih, Stephanie A. Harmon, Piyush K. Agarwal, Andrea B. Apolo, Deborah E. Citrin, James L. Gulley, Mukesh Harisinghani, Ravi A. Madan, et al.

    OBJECTIVE. The objective of our study was to evaluate the utility of ferumoxytol-enhanced MR lymphography (MRL) in detection of metastatic lymph nodes (LNs) in patients with prostate, bladder, and ...


  • Open Access

    A spontaneously metastatic model of bladder cancer: imaging characterization

    by James L. Tatum, Joseph D. Kalen, Paula M. Jacobs, Lilia V. Ileva, Lisa A. Riffle, Melinda G. Hollingshead, James H. Doroshow

    Background: Spontaneously metastatic xenograft models of cancer are infrequent and the few that exist are resource intensive. In xenografts, caliper measurements can be used to determine primary tumor burden and response to therapy but in metastatic disease models determination of the presence of metastatic disease, metastatic burden, and response to therapy are difficult, often requiring serial necropsy. In this study we characterized the development of visceral metastases in a patient derived xenograft model (PDXM) using in vivo imaging. Results: We identified and characterized the previously unreported development of spontaneous liver and bone metastasis in a known patient derived xenograft, bladder xenograft BL0293F, developed by Jackson Laboratories and the University of California at Davis and available from the National Cancer Institute Patient-Derived Models Repository [1]. Among FDG-PET/CT, contrast-enhanced MRI and non-contrast MRI, non-contrast T2w MRI was the most effective and efficient imaging technique. On non-contrast T2 weighted MRI, hepatic metastases were observed in over 70% of animals at 52 days post tumor implantation without resection of the xenograft and in 100% of animals at day 52 following resection of the xenograft. In a group of animals receiving one cycle of effective chemotherapy, no animals demonstrated metastasis by imaging, confirming the utility of this model for therapy evaluation. There was good agreement between pathologic grade and extent of involvement observed on MRI T2w imaging. Conclusion: PDX BL0293F is a reliable visceral organ (liver) metastatic model with high penetrance in both non-aggravated and post excisional situations, providing a reliable window for therapy intervention prior to required excision of the xenograft. The imaging characteristics of this model are highly favorable for non-clinical research studies of metastatic disease when used in conjunction with non-contrast T2 weighted MRI.


  • Call for Data Standardization: Lessons Learned and Recommendations in an Imaging Study

    by Amrita Basu, Denise Warzel, Aras Eftekhari, Justin S. Kirby, John Freymann, Janice Knable, Ashish Sharma, Paula Jacobs

    PURPOSE: Data sharing creates potential cost savings, supports data aggregation, and facilitates reproducibility to ensure quality research; however, data from heterogeneous systems require retrospective harmonization. This is a major hurdle for researchers who seek to leverage existing data. Efforts focused on strategies for data interoperability largely center around the use of standards but ignore the problems of competing standards and the value of existing data. Interoperability remains reliant on retrospective harmonization. Approaches to reduce this burden are needed. METHODS: The Cancer Imaging Archive (TCIA) is an example of an imaging repository that accepts data from a diversity of sources. It contains medical images from investigators worldwide and substantial nonimage data. Digital Imaging and Communications in Medicine (DICOM) standards enable querying across images, but TCIA does not enforce other standards for describing nonimage supporting data, such as treatment details and patient outcomes. In this study, we used 9 TCIA lung and brain nonimage files containing 659 fields to explore retrospective harmonization for cross-study query and aggregation. It took 329.5 hours, or 2.3 months, extended over 6 months to identify 41 overlapping fields in 3 or more files and transform 31 of them. We used the Genomic Data Commons (GDC) data elements as the target standards for harmonization. RESULTS: We characterized the issues and have developed recommendations for reducing the burden of retrospective harmonization. Once we harmonized the data, we also developed a Web tool to easily explore harmonized collections. CONCLUSION: While prospective use of standards can support interoperability, there are issues that complicate this goal. Our work recognizes and reveals retrospective harmonization issues when trying to reuse existing data and recommends national infrastructure to address these issues.


  • Proceedings: Pathways for Successful Translation of New Imaging Agents and Modalities—Phase III Studies

    by Sanjiv S. Gambhir, Lalitha K. Shankar, Eben Rosenthal, Jason M. Warram, Munir Ghesani, Thomas A. Hope, Paula M. Jacobs, Gunilla B. Jacobson, Terri Wilson, Barry A. Siegel